Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis

Journal of Neuroimmunology

Volumn 271, Issue 1-2, 2014, Pages 66-68

  Brown, J William L ^a   Martin, Peter J ^a   Thorpe, John W ^a   Michell, Andrew W ^a   Coles, Alasdair J ^a   Cox, Amanda L ^a   Vincent, Angela ^b   Zandi, Michael S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Autoantibody; Cognition; Encephalitis; LGI1; Rituximab; VGKC

Indexed keywords

AUTOANTIBODY; CONTACTIN; CONTACTIN ASSOCIATED PROTEIN LIKE 2; CYCLOPHOSPHAMIDE; ETIRACETAM; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN; LEUCINE RICH GLIOMA INACTIVATED 1 ANTIBODY; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PROTEIN 14 3 3; PROTEIN S100B; RITUXIMAB; SODIUM; UNCLASSIFIED DRUG; VALPROIC ACID; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL COMPLEX ANTIBODY;

ADDENBROOKE COGNITIVE EXAMINATION; ADULT; AGED; AMYGDALOID NUCLEUS; ANTIBODY BLOOD LEVEL; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; AUTOIMMUNE DISEASE; BRAIN METABOLISM; CASE REPORT; CELL ASSAY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DELUSION; DISEASE COURSE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ENCEPHALITIS; FACIOBRACHIAL DYSTONIC SEIZURE; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; INSOMNIA; INSULA; LEUCINE RICH GLIOMA INACTIVATED 1 ANTIBODY ENCEPHALITIS; LYMPHOCYTOPENIA; MALE; MEMORY DISORDER; NEUROIMAGING; NEUROLOGIC EXAMINATION; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOIA; PERSECUTORY DELUSION; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; RELAPSE; REMISSION; REPEATED DRUG DOSE; SEIZURE; SODIUM BLOOD LEVEL; TEMPORAL LOBE; TREATMENT RESPONSE;

AUTOANTIBODY; COGNITION; ENCEPHALITIS; LGI1; RITUXIMAB; VGKC;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ENCEPHALITIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; PROTEINS; RECURRENCE; SEIZURES; TREATMENT OUTCOME;

EID: 84900485636     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.03.012     Document Type: Article

References (12)

1. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004, 50:3580-3590.
2. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004, 350:2572-2581.
3. Faurschou M., Jayne D.R. Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu. Rev. Med. 2013, 65:263-278.
4. Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., Peles E., Buckley C., Lang B., Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
5. Irani S.R., Stagg C.J., Schott J.M., Rosenthal C.R., Schneider S.A., Pettingill P., Pettingill R., Waters P., Thomas A., Voets N.L., Cardoso M.J., Cash D.M., Manning E.N., Lang B., Smith S.J., Vincent A., Johnson M.R. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013, (first published online September 6, 2013). 10.1093/brain/awt212.
6. Sadnicka A., Reilly M.M., Mummery C., Brandner S., Hirsch N., Lunn M.P. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 2011, 82:230-232.
7. Shin Y.W., Lee S.T., Shin J.W., Moon J., Lim J.A., Byun J.I., Kim T.J., Lee K.J., Kim Y.S., Park K.I., Jung K.H., Lee S.K., Chu K. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J. Neuroimmunol. 2013, 265:75-81.
8. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006, 54:2970-2982.
9. Titulaer M.J., McCracken L., Gabilondo I., Armangue T., Glaser C., Iizuka T., Honig L.S., Benseler S.M., Kawachi I., Martinez-Hernandez E., Aguilar E., Gresa-Arribas N., Ryan-Florance N., Torrents A., Saiz A., Rosenfeld M.R., Balice-Gordon R., Graus F., Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013, 12:157-165.
10. Vincent A., Buckley C., Schott J.M., Baker I., Dewar B.K., Detert N., Clover L., Parkinson A., Bien C.G., Omer S., Lang B., Rossor M.N., Palace J. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127:701-712.
11. Wong S.H., Saunders M.D., Larner A.J., Das K., Hart I.K. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J. Neurol. Neurosurg. Psychiatry 2010, 81:1167-1169.
12. Zandi M.S. Defining and treating leucine-rich glioma inactivated 1 antibody associated autoimmunity. Brain 2013, 136:2933-2935.